Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Base-Edited Gene Therapy for X-Linked Severe Combined Immunodeficiency
NCT06851767Phase 2Enrolling by invitation
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2025
- Primary completion
- Dec 2034
- Countries
- 1
01
Overview
A Phase 2 trial of BE-HSPC IL2RG in X-linked severe combined immunodeficiency (X-SCID), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2025; status: enrolling by invitation.
02
Drugs
BE-HSPC IL2RG
03
Conditions
X-linked severe combined immunodeficiency (X-SCID)
Beyond the preview
Go deeper on NCT06851767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851767.